Brief: Mabion Has Adopted Joint Growth Strategy To Register Mabioncd20 On Both American And European Market
02/08/2021 07:27
August 2 (Reuters) - Mabion SA MABP.WA :
* SAID ON FRIDAY THAT IT HAS ADOPTED JOINT GROWTH STRATEGY
TO
REGISTER MABIONCD20 ON BOTH AMERICAN AND EUROPEAN MARKET
FOLLOWING TALKS WITH FDA AND EUROPEAN MEDICINES REGULATORY
BODIES
* COMPANY HAS ESTABLISHED ITS FINAL DATA SCOPE REQUIRED TO
REGISTER AND DISTRIBUTE MABIONCD20 ON EUROPEAN MARKET
Source text for Eikon: urn:newsml:reuters.com:*:nEM1DJvRTa
Further company coverage: MABP.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects